Background
Methods
Patients and samples
Clincopathological factors | Number |
---|---|
Sex
| |
Male | 147 |
Female | 104 |
pT stage
| |
1 | 10 |
2 | 41 |
3 | 171 |
4 | 29 |
pN stage
| |
0 | 136 |
1 | 75 |
2 | 40 |
Vascular invasion
| |
0 | 219 |
1 | 32 |
Lymphatic invasion
| |
0 | 212 |
1 | 39 |
TNM stage
| |
I | 35 |
II | 98 |
III | 105 |
IV | 13 |
Western blot assay
Tissue microarray
Immunohistochemical analysis
IHC data analysis
Statistical analysis
Results
Cyr61 protein expression in CRC cell lines and normal-cancer paired CRC tissues by western blot
Cyr61 expression in CRC tissue by Immunohistochemistry
Clincopathological factors | Cyr61 | Total (%) | p | |
---|---|---|---|---|
Positive N = 157 (%) | Negative N = 94 (%) | |||
Age, years, mean (SD)
| 62.2 (12.2) | 65.2 (11.5) | 63.3 (12.0) | 0.061 |
Sex
| 0.296 | |||
Male
| 88 (56.1) | 59 (62.8) | 147 (58.6) | |
Female
| 69 (43.9) | 35 (37.2) | 104 (41.4) | |
pT stage
| 0.021 | |||
1
| 8 (5.1) | 2 (2.1) | 10 (4.0) | |
2
| 20 (12.7) | 21 (22.3) | 41 (16.3) | |
3
| 105 (66.9) | 66 (70.2) | 171 (68.1) | |
4
| 24 (15.3) | 5 (5.3) | 29 (11.6) | |
pN stage
| 0.006 | |||
0
| 73 (46.5) | 63 (67.0) | 136 (54.2) | |
1
| 56 (35.7) | 19 (20.2) | 75 (29.9) | |
2
| 28 (17.8) | 12 (12.8) | 40 (15.9) | |
Vascular invasion
| 0.700 | |||
0
| 136 (86.6) | 83 (88.3) | 219 (87.3) | |
1
| 21 (13.4) | 11 (11.7) | 32 (12.7) | |
Lymphatic invasion
| 0.563 | |||
0
| 131 (83.4) | 81 (86.2) | 212 (84.5) | |
1
| 26 (16.6) | 13 (13.8) | 39 (15.5) | |
TNM stage
| 0.001 | |||
I
| 17 (10.8) | 18 (19.1) | 35 (13.9) | |
II
| 51 (32.5) | 47 (50.0) | 98 (39.0) | |
III
| 79 (50.3) | 26 (27.7) | 105 (41.8) | |
IV
| 10 (6.4) | 3 (3.2) | 13 (5.2) |
Clinicopathological factors | Univariate analysis | Multivariate analysis | ||
---|---|---|---|---|
Hazard ratio (95% CI) | P | Hazard ratio (95% CI) | P | |
Age
| 1.01 (0.99–1.03) | 0.514 | 1.00 (0.98–1.03) | 0.858 |
Sex (0 = male, 1 = female)
| 1.03 (0.60–1.77) | 0.917 | 1.20 (0.66–2.20) | 0.548 |
pT stage
| ||||
1
| 1.00 | 1.00 | ||
2
| 1.09 (0.24–5.03) | 0.916 | 0.93 (0.18–4.86) | 0.927 |
3
| 1.13 (0.27–4.70) | 0.864 | 0.99 (0.19–4.88) | 0.967 |
4
| 3.44 (0.68–17.78) | 0.140 | 2.15 (0.34–13.86) | 0.419 |
pN stage
| ||||
0
| 1.00 | 1.00 | ||
1
| 1.83 (0.99–3.40) | 0.056 | 2.02 (1.04–3.94) | 0.038 |
2
| 2.90 (1.44–5.83) | 0.003 | 2.53 (1.20–5.32) | 0.015 |
Venous invasion
| 1.00 (0.45–2.21) | 0.991 | 0.67 (0.23–1.96) | 0.463 |
Lymphatic invasion
| 1.84 (0.98–3.44) | 0.057 | 1.97 (0.79–4.90) | 0.143 |
Differentiation
| ||||
Well
| 1.00 | 1.00 | ||
Moderate
| 0.70 (0.36–1.40) | 0.298 | 0.61 (0.28–1.30) | 0.198 |
Poor
| 0.86 (0.24–3.08) | 0.817 | 0.75 (0.18–3.09) | 0.692 |
Cyr61 Expression
| ||||
Negative
| 1.00 | 1.00 | ||
Negative to mild expression
| 0.89 (0.48–1.67) | 0.721 | 0.86 (0.44–1.70) | 0.662 |
Moderate to severe expression
| 2.56 (1.29–5.08) | 0.007 | 2.31 (1.09–4.89) | 0.029 |